Shaughn Bryant
Overview
Explore the profile of Shaughn Bryant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
226
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McPherson M, Hobson A, Hernandez Jr A, Marvin C, Waegell W, Goess C, et al.
Sci Transl Med
. 2024 Mar;
16(739):eadd8936.
PMID: 38507467
Glucocorticoids (GCs) are efficacious drugs used for treating many inflammatory diseases, but the dose and duration of administration are limited because of severe side effects. We therefore sought to identify...
2.
Lord A, Zhang L, Erickson J, Bryant S, Nelson C, Gaudette S, et al.
Sci Rep
. 2022 Feb;
12(1):2863.
PMID: 35190580
A painful, chronic condition, Rheumatoid Arthritis, is marked by bone erosion and soft tissue swelling at the joint. As treatments are investigated in pre-clinical models, characterizing disease progression is integral...
3.
Ruzek M, Huang L, Zhang T, Bryant S, Slivka P, Cuff C, et al.
J Pharmacol Exp Ther
. 2018 Jan;
364(3):474-484.
PMID: 29311111
Despite the efficacy of biologics for treatment of rheumatoid arthritis (RA), many patients show inadequate responses and likely require neutralization of multiple mediators. Neutralization of both interleukin (IL)-1 and IL-17A...
4.
Schmidt Paustian A, Paez-Cortez J, Bryant S, Westmoreland S, Waegell W, Kingsbury G
PLoS One
. 2017 Aug;
12(8):e0182841.
PMID: 28792532
Mutations in the Interleukin (IL)-23/IL-23 receptor loci are associated with increased inflammatory bowel disease (IBD) susceptibility, and IL-23 neutralization has shown efficacy in early clinical trials. To better understand how...
5.
McRae B, Levin A, Wildenberg M, Koelink P, Bousquet P, Mikaelian I, et al.
J Crohns Colitis
. 2015 Oct;
10(1):69-76.
PMID: 26429698
Background And Aims: Anti-tumour necrosis factor [TNF] monoclonal antibodies [infliximab, adalimumab] induce complete mucosal healing in a proportion of patients with Crohn's disease whereas a TNF receptor fusion protein [etanercept]...
6.
Bardwell P, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, et al.
J Immunol
. 2009 Jun;
182(12):7482-9.
PMID: 19494271
The Bcl-2 family of proteins plays a critical role in controlling immune responses by regulating the expansion and contraction of activated lymphocyte clones by apoptosis. ABT-737, which was originally developed...
7.
Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al.
Nat Biotechnol
. 2007 Oct;
25(11):1290-7.
PMID: 17934452
For complex diseases in which multiple mediators contribute to overall disease pathogenesis by distinct or redundant mechanisms, simultaneous blockade of multiple targets may yield better therapeutic efficacy than inhibition of...